<DOC>
	<DOC>NCT02704364</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Sclerosing Cholangitis.</brief_summary>
	<brief_title>Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis, Sclerosing</mesh_term>
	<criteria>Confirmed diagnosis of PSC Clinically significant acute or chronic liver disease of an etiology other than PSC Secondary or IgG4 related sclerosing cholangitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>